Cargando…

Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial

Vilazodone is a selective serotonin reuptake inhibitor and 5-HT(1A) partial agonist approved for major depressive disorder (MDD) treatment in adults. This was a 10-week, multicenter, double-blind, placebo-controlled and active-controlled, fixed-dose trial (NCT01473381). Adult patients with MDD (Diag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mathews, Maju, Gommoll, Carl, Chen, Dalei, Nunez, Rene, Khan, Arif
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams And Wilkins 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4314105/ https://www.ncbi.nlm.nih.gov/pubmed/25500685 http://dx.doi.org/10.1097/YIC.0000000000000057

Ejemplares similares

Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial
por: Clayton, Anita H., et al.
Publicado: (2015)

Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study
por: Gommoll, Carl, et al.
Publicado: (2015)

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FIXED-DOSE PHASE III STUDY OF VILAZODONE IN PATIENTS WITH GENERALIZED ANXIETY DISORDER
por: Gommoll, Carl, et al.
Publicado: (2015)

Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial
por: Citrome, Leslie, et al.
Publicado: (2015)

Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials
por: Thase, Michael E., et al.
Publicado: (2017)

Effects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo-controlled, and active-controlled study
por: Clayton, Anita H., et al.
Publicado: (2017)

Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial
por: Durgam, Suresh, et al.
Publicado: (2018)

Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone
por: Khan, Arif, et al.
Publicado: (2016)

Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials
por: Kornstein, Susan, et al.
Publicado: (2018)

A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder
por: Gommoll, Carl P., et al.
Publicado: (2014)

Clinical Relevance of Vilazodone Treatment in Patients With Major Depressive Disorder: Categorical Improvement in Symptoms
por: Culpepper, Larry, et al.
Publicado: (2014)

Categorical improvements in disease severity in patients with major depressive disorder treated with vilazodone: post hoc analysis of four randomized, placebo-controlled trials
por: Durgam, Suresh, et al.
Publicado: (2016)

Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder
por: Thase, Michael E., et al.
Publicado: (2014)

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder
por: Durgam, Suresh, et al.
Publicado: (2018)

Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials
por: Montgomery, Stuart A., et al.
Publicado: (2014)

Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression
por: Khan, Arif, et al.
Publicado: (2014)

Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials
por: Sambunaris, Angelo, et al.
Publicado: (2014)

A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up
por: Findling, Robert L., et al.
Publicado: (2020)

An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2022)

A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder
por: Sambunaris, Angelo, et al.
Publicado: (2014)

A Review of Vilazodone, Serotonin, and Major Depressive Disorder
por: Pierz, Kerri A., et al.
Publicado: (2014)

Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies
por: Clayton, Anita H, et al.
Publicado: (2016)

The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study
por: Montgomery, Stuart A., et al.
Publicado: (2014)

Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
por: Zhang, Xiao-Fei, et al.
Publicado: (2015)

The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder
por: Sahli, Zeyad T., et al.
Publicado: (2016)

A Phase III Prospective Active and Placebo-Controlled Randomized Trial of Vilazodone in the Treatment of Major Depressive Disorder
por: Sinha, Shubhadeep, et al.
Publicado: (2021)

Vilazodone for the Treatment of Depression: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice
por: Chauhan, Mohit, et al.
Publicado: (2022)

Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action
por: Wang, Sheng-Min, et al.
Publicado: (2015)

Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy
por: Hellerstein, David J, et al.
Publicado: (2015)

Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
por: Singh, Mandeep, et al.
Publicado: (2012)

An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023)

Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial)
por: Patel, Jaimin M, et al.
Publicado: (2012)

Randomized trial of vilazodone versus sertraline in depression: Concerns and comments
por: Praharaj, Samir Kumar
Publicado: (2021)

A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis
por: Iwakiri, Katsuhiko, et al.
Publicado: (2017)

Efficacy and tolerability of vilazodone for major depressive disorder: evidence from phase III/IV randomized controlled trials
por: Shi, Ligen, et al.
Publicado: (2016)

Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality
por: Fu, Dong-Jing, et al.
Publicado: (2023)

Vilazodone-Induced Hyperglycemia: A Case Series
por: Das, Abhipsa, et al.
Publicado: (2020)

Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder
por: Boulenger, Jean-Philippe, et al.
Publicado: (2014)

Morning and evening efficacy evaluation of rupatadine (10 and 20 mg), compared with cetirizine 10 mg in perennial allergic rhinitis: a randomized, double-blind, placebo-controlled trial
por: Marmouz, Farid, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_h4c1d3cfqpld9thda65j3k75u1